What TRIUMPH-3 tells us about maintenance, and what it does not
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
Trial design
Page 30 of 32 of this archive, newest first.
From the floor in Changsha: 11 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Why "muscle-sparing" is a marketing term and not a measurement
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
SURMOUNT-1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Percentage of loss, absolute kilograms, and the sleight of hand between them
A substudy powered to describe a mean is not a substudy powered to detect a clinically meaningful individual change.
SELECT misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURMOUNT-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
SURPASS-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
SURMOUNT-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Two sessions a week, and the evidence behind the prescription
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
TRIUMPH-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
What the outcome trials measured in the kidney
Asymptomatic pancreatic enzyme elevation is common on treatment and is not pancreatitis. The distinction is clinical, not biochemical.
FLOW extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.